124i-meta-iodobenzylguanidine

Small moleculeexperimentalImaging agent

Clinical trial activity

4 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
4
Phase 3
1
Phase 4
0

Earliest trial started Dec 5, 2001 (NCT00028106)

Timeline

2000s

  1. Jan 1, 2001

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2014

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2015

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetRadiopharmaceutical

    radiopharmaceutical

Chemistry & pharmacology

Imaging
124-iodine

Oral

No

Parenteral

No

Topical

No

Also known as

  • 124i-meta-iodobenzylguanidine

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02071680Phase 3Mar 31, 2015University of Ottawa
NCT02043899Phase 1/Phase 2 (Phase 2)Feb 1, 2014Cancer Research UK
NCT01931488Phase 2Aug 31, 2013Tel Aviv University
NCT00028106Phase 2Dec 5, 2001National Institutes of Health (NIH)
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Cancer Research UKAcademic/Hospital1112014
National Institutes of Health (NIH)Government1112001
Tel Aviv UniversityAcademic/Hospital1112013
University of OttawaAcademic/Hospital1112015
4 organizations
Page 1 / 1